176 related articles for article (PubMed ID: 38225166)
1. Determination of vWF, ADAMTS-13 and Thrombospondin-1 in Venous Thromboembolism and Relating Them to the Presence of Factor V Leiden Mutation.
Al-Awadhi A; Marouf R; Jadaon MM; Al-Awadhy MM
Clin Appl Thromb Hemost; 2024; 30():10760296231223195. PubMed ID: 38225166
[TBL] [Abstract][Full Text] [Related]
2. Impact of the von Willebrand factor-ADAMTS-13 axis on the risk of future venous thromboembolism.
Edvardsen MS; Hansen ES; Ueland T; Aukrust P; Brækkan SK; Morelli VM; Hansen JB
J Thromb Haemost; 2023 May; 21(5):1227-1237. PubMed ID: 36736832
[TBL] [Abstract][Full Text] [Related]
3. Relationship of Thrombospondin 1 to von Willebrand Factor and ADAMTS-13 in Sickle Cell Disease Patients of Arab Ethnicity.
Al-Awadhi A; Adekile A; Marouf R
Acta Haematol; 2021; 144(2):182-189. PubMed ID: 32987383
[TBL] [Abstract][Full Text] [Related]
4. Evaluating von Willebrand factor and ADAMTS13 levels in thalassemia major patients and assessing a possible association with Thrombospondin-1.
Al-Sabaan K; Al-Awadhi A
Int J Lab Hematol; 2023 Dec; 45(6):945-952. PubMed ID: 37438087
[TBL] [Abstract][Full Text] [Related]
5. Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
Karakaya B; Tombak A; Serin MS; Tiftik N
Hematology; 2016 Jun; 21(5):295-9. PubMed ID: 26872106
[TBL] [Abstract][Full Text] [Related]
6. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
Pépin M; Kleinjan A; Hajage D; Büller HR; Di Nisio M; Kamphuisen PW; Salomon L; Veyradier A; Stepanian A; Mahé I
J Thromb Haemost; 2016 Feb; 14(2):306-15. PubMed ID: 26589836
[TBL] [Abstract][Full Text] [Related]
7. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
[TBL] [Abstract][Full Text] [Related]
8. The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study.
Obermeier HL; Riedl J; Ay C; Koder S; Quehenberger P; Bartsch R; Kaider A; Zielinski CC; Pabinger I
Res Pract Thromb Haemost; 2019 Jul; 3(3):503-514. PubMed ID: 31294335
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.
Al-Awadhi A; Adekile A; Marouf R
J Thromb Thrombolysis; 2017 Jan; 43(1):117-123. PubMed ID: 27613177
[TBL] [Abstract][Full Text] [Related]
10. von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications.
Calabrò P; Gragnano F; Golia E; Grove EL
Semin Thromb Hemost; 2018 Apr; 44(3):249-260. PubMed ID: 28898897
[TBL] [Abstract][Full Text] [Related]
11. von Willebrand factor/ADAMTS-13 interactions at birth: implications for thrombosis in the neonatal period.
Katneni UK; Ibla JC; Hunt R; Schiller T; Kimchi-Sarfaty C
J Thromb Haemost; 2019 Mar; 17(3):429-440. PubMed ID: 30593735
[TBL] [Abstract][Full Text] [Related]
12. Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation.
Saemundsson Y; Sveinsdottir SV; Svantesson H; Svensson PJ
J Thromb Thrombolysis; 2013 Oct; 36(3):324-31. PubMed ID: 23054468
[TBL] [Abstract][Full Text] [Related]
13. Smoking, von Willebrand factor and ADAMTS-13 in healthy males.
Al-Awadhi AM; Jadaon MM; Alsayegh FA; Al-Sharrah SK
Scand J Clin Lab Invest; 2012 Dec; 72(8):614-8. PubMed ID: 23020229
[TBL] [Abstract][Full Text] [Related]
14. Gender-related differences in the outcome of patients with venous thromboembolism and thrombophilia.
Tzoran I; Papadakis E; Brenner B; Valle R; López-Jiménez L; García-Bragado F; Riera-Mestre A; Villalobos A; Quintavalla R; Monreal M;
Thromb Res; 2017 Mar; 151 Suppl 1():S11-S15. PubMed ID: 28262227
[TBL] [Abstract][Full Text] [Related]
15. von Willebrand factor propeptide-to-antigen ratio in HIV-infected pregnancy: Evidence of endothelial activation.
Schapkaitz E; Libhaber E; Jacobson BF; Meiring M; Büller HR
J Thromb Haemost; 2021 Dec; 19(12):3168-3176. PubMed ID: 34409729
[TBL] [Abstract][Full Text] [Related]
16. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis.
van Vlijmen EF; Wiewel-Verschueren S; Monster TB; Meijer K
J Thromb Haemost; 2016 Jul; 14(7):1393-403. PubMed ID: 27121914
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of recurrent venous thromboembolism in patients with Factor V Leiden mutation in heterozygous form.
Sveinsdottir SV; Saemundsson Y; Isma N; Gottsäter A; Svensson PJ
Thromb Res; 2012 Sep; 130(3):467-71. PubMed ID: 22512897
[TBL] [Abstract][Full Text] [Related]
18. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis.
Favaloro EJ; Henry BM; Lippi G
Semin Thromb Hemost; 2021 Jun; 47(4):400-418. PubMed ID: 33893632
[TBL] [Abstract][Full Text] [Related]
19. Elevated Von Willebrand Factor Antigen Levels are an Independent Risk Factor for Venous Thromboembolism: First Report from North India.
Rajpal S; Ahluwalia J; Kumar N; Malhotra P; Uppal V
Indian J Hematol Blood Transfus; 2019 Jul; 35(3):489-495. PubMed ID: 31388262
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ADAMTS-13 by Doxycycline Reduces von Willebrand Factor Degradation During Supraphysiological Shear Stress: Therapeutic Implications for Left Ventricular Assist Device-Associated Bleeding.
Bartoli CR; Kang J; Restle DJ; Zhang DM; Shabahang C; Acker MA; Atluri P
JACC Heart Fail; 2015 Nov; 3(11):860-9. PubMed ID: 26454844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
